Skip to main content

Table 2 Baseline characteristics of patients in the validated per protocol (VPP) population

From: Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial

 CTRX (n = 104)ABPC/SBT (n = 108)p-value
Male/female, n (% male)55/49 (53)60/48 (56)0.78*
Age, y59.0 ± 21.663.2 ± 18.90.13
Comorbidities*
 Cancer8 (8)12 (11)0.48*
 Hematological malignancy2 (2)0 (0)0.24
 Cardiovascular disease7 (7)12 (11)0.34*
 Chronic lung disease21 (20)19 (18)0.73*
 Bronchial asthma11 (11)10 (9)0.82*
 COPD6 (6)6 (6)1.00*
 Chronic liver disease1 (1)0 (0)0.49
 Chronic kidney disease2 (2)2 (2)1.00
Pneumonia severity index66.3 ± 32.568.5 ± 26.70.60
 Class I, n (%)26 (25)20 (19)0.63
 Class II, n (%)35 (34)36 (33)
 Class III, n (%)20 (19)38 (35)
 Class IV, n (%)19 (18)11 (10)
 Class V, n (%)4 (4)3 (3)
Performance status, n (%)
 093 (89)98 (91)0.76
 19 (9)8 (7)
 22 (2)1 (1)
 30 (0)1 (1)
 40 (0)0 (0)
Maximum body temperature, °C
 Before treatment38.1 ± 0.938.1 ± 1.00.77
 Day of visit38.0 ± 0.938.1 ± 1.00.77
Systolic blood pressure, mmHg127.8 ± 20.9132.0 ± 24.40.18
Diastolic blood pressure, mmHg73.0 ± 16.273.3 ± 13.40.90
Pulse rate, beats/min91.2 ± 17.289.2 ± 15.80.36
Respiration rate, breaths/min (n)21.1 ± 4.9 (68)22.0 ± 5.3 (77)0.31
CRP, mg/dL11.0 ± 7.112.5 ± 7.50.12
WBC, ×103/μL11.7 ± 4.911.0 ± 5.30.37
Albumin, g/dL (n)3.8 ± 0.5 (103)3.8 ± 0.4 (106)0.97
  1. CTRX Ceftriaxone, ABPC/SBT Ampicillin/sulbactam, CRP C-reactive protein, WBC White blood cell. Data are presented as mean ± standard deviation (SD) for continuous variables and number (%) for categorical variables. Comparisons were conducted using Student’s t-test unless otherwise indicated. *Chi-squared test. Fisher exact test. Mann–Whitney U test